<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background Cetuximab-induced <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> has been associated with improved clinical outcomes in advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We explored this relationship from a randomized clinical trial of cetuximab plus best supportive care (BSC) versus BSC alone in patients with pretreated advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients and methods Day 28 <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> grade (0 versus ≥1) and percent reduction (&lt;20% versus ≥20%) of Mg from baseline was correlated with outcome </plain></SENT>
<SENT sid="3" pm="."><plain>Results The median percentage Mg reduction at day 28 was 10% (-42.4% to 63.0%) for cetuximab (N = 260) versus 0% (-21.1% to 25%) for BSC (N = 251) [P &lt; 0.0001] </plain></SENT>
<SENT sid="4" pm="."><plain>Grade ≥1 <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> and ≥20% reduction from baseline at day 28 were associated with worse overall survival (OS) [hazard ratio, HR 1.61 (95% CI 1.12-2.33), P = 0.01 and 2.08 (95% CI 1.32-3.29), P = 0.002, respectively] in multivariate analysis including grade of <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> (0-1 versus 2+) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002094'>Dyspnea</z:hpo> (grade ≥3) was more common in patients with ≥20% versus &lt; 20% Mg reduction (68% versus 45%; P = 0.02) and grade 3/4 <z:hpo ids='HP_0002039'>anorexia</z:hpo> were higher in patients with grade ≥1 <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> (81% versus 63%; P = 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>Conclusions In contrast to prior reports, cetuximab-induced <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo> was associated with poor OS, even after adjustment for grade of <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
</text></document>